Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 6/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27807069 | 0.89 | MAPT (0.50) | MAPTRECQLALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL591950 | 0.87 | SIRT6 (0.62) | MAPTALDH1A1MAPK1SIRT6HTR6 | |
| SCHEMBL23044900 | 0.87 | SIRT6 (0.61) | MAPTRECQLALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1375198 | 0.86 | MAPT (0.60) | MAPTALDH1A1SMN1; SMN2MAPK1CYP2C9 | |
| SCHEMBL3512166 | 0.85 | MAPT (0.53) | MAPTALDH1A1POLBMAPK1SIRT6 | |
| SCHEMBL21430924 | 0.84 | MAPT (0.55) | MAPTRECQLALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL1888701 | 0.83 | ALDH1A1 (0.51) | MAPTALDH1A1MAPK1SIRT6CYP1A2 | |
| SCHEMBL589675 | 0.83 | SIRT6 (0.57) | MAPTALDH1A1MAPK1SIRT6CYP1A2 | |
| Hydrochloric Acid SCHEMBL23044907 | 0.83 | MAPT (0.54) | MAPTRECQLALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL591100 | 0.82 | PLK1 (0.46) | MAPTALDH1A1SIRT6CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118530239-A | Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-04-30 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-8673893-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-18 | — | — | US | disclosed |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-17 | — | — | US | disclosed |
| US-8299057-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-30 | — | — | US | disclosed |
| US-8173659-B2 | Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-05-08 | — | — | US | disclosed |
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-22 | — | — | US | disclosed |
| US-7947686-B2 | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-24 | — | — | US | disclosed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | disclosed |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-22 | — | — | US | disclosed |
| EP-1968976-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007068619-A1 | SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K3, MAP3K1, MAP3K19 | MAPT 2600/4885RECQL 2899/4885ALDH1A1 2295/4885 |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | MAPT 2440/4885RECQL 2944/4885ALDH1A1 1805/4885 |
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | MAPT 650/4885RECQL 1731/4885ALDH1A1 4113/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | MAPT 650/4885RECQL 1731/4885ALDH1A1 4113/4885 |
| US-20130018036-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | MAPT 2440/4885RECQL 2944/4885ALDH1A1 1805/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | MAPT 2026/4885RECQL 4049/4885ALDH1A1 4483/4885 |
| US-20240400570-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | MAPT 650/4885RECQL 1731/4885ALDH1A1 4113/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | MAPT 3010/4885RECQL 384/4885ALDH1A1 1427/4885 |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, NTRK1, ERBB2 | MAPT 554/4885RECQL 1965/4885ALDH1A1 3928/4885 |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K19 | MAPT 2600/4885RECQL 2899/4885ALDH1A1 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.